Johnson & Johnson is preparing regulatory submissions for icotrokinra, its first-in-class oral therapy for psoriasis, after the drug hit its main goals in two Phase III studies.
Key Takeaways
J&J's interleukin-23 receptor blocker has hit in two Phase III psoriasis trials, with regulatory filings planned.
The once-daily pill could provide strong competition to BMS's TYK2 inhibitor Sotyktu and a head-to-head study is ongoing.
Originator Protagonist Therapeutics is now set to receive $165m in milestone payments in the first quarter of 2025.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?